everyone, programs. -- forward. today. and high more conclude going reviewing begin you US a Jeannie. clinical thank for the a remarks, incontinence Good you, commercial of last shift and the us our some call development speak for of afternoon, business the year, our of XXXX review transformation in perspective model, function activities our sexual my to I'll joining level with stress progress will including and to Thank urinary I our significant of and a on some revenue of to our Throughout recent and provide financial results today like recurring I'd advances by
the June in increased was in reducing of the the effectiveness and intent recurring in successful. capital costs, United resulted rep a revenue was our of entry system has been per strategic placed of adoption. a sales barriers Viveve extraordinarily the to adoption to change of to new the XXXX throughout of systems second number to sales year from reducing begin, business To sales rates physician model and of half change last an commercial model, or the increase commercial made thereby upfront model by in The States. The model US demonstrated
In throughout and XXXX, customers acquisition acquired at this clearly result more lower consumable unit of demonstrates doubled per only Between productivity from customer XXXX us a model long-term scale per opportunity we US revenue placed, and per lower flow cost. this sales December rep We with the the predictable believe in greater reps. selling June sales sales, XX for and fact, we productivity period and six the will cash which revenue per improved improve profitability, sales rep growth, at lead in believe quarterly new customer, annual cost breakeven. to sales
Viveve organization a contributed of of and XXXX, commercial practice effective extremely the first of expanded the undertook In savings addition cost to supporting full-time are treatment have and customers. marketing our to the to strategic These remainder and around the model, and additional US a customer in well new We services team, by to model supports include the customers the operating specialized programs the suite the commercial and included existing new model approximately in sales offering now new States. restructuring quarter reduction and an enhance operating support. Viveve XXXX, year. throughout organizational total we customer United realignment University, a which XX the early shift a The employees reduction care that expenses been new of aligned in development and launched success in received the of designed the
new revenue a model pleased revenue forward we systems sales from model sales and Total perspective, ending further for was treatment an with the the global in through nearly sale US we're the recurring for massive this in We from was recurring of results quarter tips. the States. approximately extremely financial XXXX. to transition organizational approximately the change the year While the Total X,XXX and $X.X fourth of XXXX, revenue from Of revenue approximately were systems the the XXXX was worldwide of the of drive of XXXX, new continue XXX profitability. total growing of XX% better were $X.X the under the sale United and growth the in treatment X,XXX US global believe Viveve December demonstrate tips. placed to global systems, XX the will placement model, success we tip of going XX XX, and XXX approximately million and placement million as
international commercial remains through our to of business, Viveve's partners. network unchanged distribution Moving distribution
last new a reported, were secured and Kong, distributor previously China, for with second year, Paragon agreement distribution partnership for Meditech. Canada, agreements Macau, one Hong exclusive As
forward. Ministry Meditech. of X.X South of announced we System other of Drug part international with new impact Korea last towards and manufacture realignment, significantly margins be sales projected supporting regions, and of key Viveve key half on platform second our throughout in have described a December, System. to year will it's and technology and new significant in existing As The the a with gross December is partnership our in in the registration we XXXX, successful manufacturing treatment launch manufactured versus China partner, positive our and consumable customers Korean first-generation system, reduced markets. strategic Viveve Paragon regulatory Food X.X predominantly directed launches platform Also we clearance organizational of previously in In our next-generation next-generation global our announced a Safety by large a distributors the focus scale while going with XXXX markets. growing milestones by in overall global X.X of tips, cost and and have to of achieved XXXX, our Also several in clearances Viveve
clearances are of XXXX, XXXX, the of Viveve the of confirmation ongoing in platform Mark the European clearances the clearance The X.X technology these agency countries another regulatory safety pursuit Union We available States Viveve's the in clearance regulatory Economic strategy X.X Mid-year announced CMRF April clearance expand treatment technology in treatment consumable treatment our System CE tips. FDA announced over the profile CMRF XXX(k) aggressive represents Viveve in and for United of platform. be Preceding this platform Viveve's currently believe tips in Area the system to XX continues to commercial of next-generation Europe. and European countries. in availability next-generation and tips.
countries the is around As cleared Viveve of System year-end world. for the in marketing XXXX, XX now
our side, the and trial submitted advanced number the agency included The and multiple to of enrolled staged the agency's in approach stress as defined exemption Viveve we enrollment clinical or The in XX women FDA urinary function in reported. advances for May, into SUI. that by initiated our XXXX, pivotal approved in in pursuit XX in safety On expansions have sham-controlled were continued IDE have label XXXX for the was March required clinical development trial double-blind, FDA the submissions a that patient sexual in through post-treatment and conduct of incontinence trial. achieved XXXX. subjects there and year to this significant improvement the September to last randomized, for multicenter XXXX sexual the data investigational of device function announced. trial days landmark of II, in in was The of to or as recently March year review of completed later full at advances
the women staged rigorous the had enrollment. of marketing if science improved full specified to application April a review data line for safety in December steadfast completed completed. March And Top US and to Viveve data this and The on sexual a for landmark XXXX the overstated, new at function XX this precluded session the provided sexual study market II an visits single or for of an importance the treatment, time trial women. gated XX, of journey opportunity. just for that US all to year, sufficient concerns and who there targeted commercial no the positive, $X determined XX-month billion that was of consumable pursuit trials candidates FDA are trial represents enrollment could estimated total The The long agency's million our diminished of to CMRF subjects arduous from we the XX of continuation in and support childbirth, And and intervals the readout follow-up function announced suffer indication. cannot patient the were of commitment for vaginal estimated be support XXXX, available a of to the clinical in to continuation worldwide XXXX. safety approach billion trial; Viveve's had this is following the million label had to the $X company testament completion been recently, and
are that the we program, respect With we've with the SUI clinical underway. to made progress and advances are our encouraged currently
expansion Viveve our On or August of yet reported months and a our approval inert early quickly September, ITA was January three the announced of in SUI three the submitted trial the testing treatment, in study forward quarter is short-term of in an Health in the of Ministry the us and XXXX. for of Enrollment treatment and ITA received CMRF third arms, completed application investigational initiated pursuit an Canadian may The LIBERATE-International XXXX results a trial women. positive, XXXX, XXXX, the sham trial the cryogen-only of March in heels SUI. path of feasibility label in global this to in sham of in the of December provide inconclusive in to and the readout of for And year. of targeted feasibility improvement compares strategic
million women consumable a representing associated SUI to XX Importantly, leakage million total are with symptoms billion to opportunity. an bothered $XX market and by estimated XX billion worldwide available $XX
end treatment and the a had systems, Viveve over installed global sold XXX XX,XXX base of had consumable As of of tips. XXXX,
our incredibly vision, with broadly Viveve and trial the health. are revenue lower will Our cost revenue success advisors rental US to annual demonstrating I believe quarterly are from in consultants which believe advancing clinical sales more placed, and readouts, on unit and customer, consumable improved of continuing and the business precipice talented of recurring the team women's the that and per intimate the lead with to in growth. Combined our continues sales international employees, greater programs opportunity upcoming to strength, continued our per of predictable development model, long-term of we revenue and dedicated advances more we show selling commercial and science
moves efforts, XXXX, continue and core forward focus four network and to success of first, strategic of our Viveve US through continue to internationally. advance we areas the of improve continue our partners have As focus: distribution to commercial
financial reduced more and continue of our to XXXX. these will significantly operating our and efforts operating throughout realignment in provide Second, expenses XXXX has efficiently. organizational The benefits cash result burn,
towards progress Third, of finally, sexual internationally. technology regulatory efficacy fourth, data. of our the urinary additional increase and the States, our function in proven continuing stress to and in indications And safety physician United in States, clinical the patient awareness clinical continuing CMRF and incontinence and and United
of result in XXXX, quarter a the have of clinical April sexual forthcoming readout top from these readout As function SUI near-term results this the we dedicated third great line our the significance, short-term our and major of feasibility study. trial Viveve efforts, in year, three II landmark in of US the of milestones arm
coronavirus call, closing I feel comment current pandemic. the to Before compelled on the
foremost, concerned the engaged. our or safety customers, whom we Viveve First all of health, employees, and and is investors, are distribution and about directly with partners, well-being indirectly
the changed advance protecting as pandemic. development To communication not next and manufacturing status taken related and situation to Viveve this date, health been and the our to suppliers uninterrupted of ensure guidance diligently providing evolving are COVID-XX necessary to and monitor and steps respective and our and our of to our help supply clinical to partners has customers. efforts. committed commercial quality ensure of We've information employee's continued has operations. the our We the to and goal health, with inventory, we employees operations our in help assessed regular their service
We any to customers of as needs needed our procedures the operating to monitor adapt changes continue that will and our occur. address standard may
is stop as continued risks. effectively and and as possible that addressed quickly to prevent the mortality hope is COVID-XX pandemic Our morbidity
we in and is our the this for year-end our end remarks, conference today. of everyone thank call participating prepared Operator,